
Diabetic Foot Ulcers




Student: Sezim Seno

Epidemiology of Diabetic Foot

- Diabetic Foot Ulcers(DFU) are common complications of poorly controlled diabetes mellitus (DM)
- The global prevalence of diabetes mellitus is estimated 382mln including the US
- DFU complication problems affects 131 mln globally
- Morbidity: Approximately 15% of diabetic patients develop DFU in their lifetime
- Recurrence rates 65% of patients (3-5 years)
- Amputation incidence is 20%
- Mortality after DFU is 50-70%
- Current economic burden of DFU and amputations in US is 11 billion

Wound Management & Prevention L Home



Disparities of DFU

Age:

- The risk of DFU is increase with age, duration of DM
- Young and middle age people have more advanced foot ulceration due to poor lifestyle, high A1C, higher PN and smoking

Sex/Gender:

- DFU is 1.5 higher in males than in females
- Minor and major amputation is also higher in men(because of underlying risk factor, access to care, screening, and adherence to treatment)

Race/ Ethnicity

• Black, Hispanic and other non-white adults experience in higher rates




Etiology of Diabetic Foot Ulcer

Formation of DFU is multifactorial

- Poor management of DM and chronic hyperglycemia
- Peripheral Neuropathy(PN)
- Peripheral Vascular Disease (PVD) due to atherosclerosis→poor circulation→ tissue ischemia
- Peripheral Artery Disease (PAD)
- Calluses or foot deformities, muscle dystrophy
- Improper footwear & care (causes foot injury)
- Repetitive mechanical trauma of the foot or toes
- Infections of the foot / previous healed ulcer

DFUs are classified into 3 types:

- 1. Purely neuropathic 35%
- 2. Purley Ischemic 15%
- 3. Mixed neuroischemic 50%




Neuropathy → **Neuropathic Ulcers**

60% of DM ${\rightarrow} Neuropathy {\rightarrow} DFU$

Neuropathy is a nerve damage due to high blood sugar, causes numbness, tingling, a burning feeling, pain, cramps or weakness in the hands and feet, further may spread into limbs

- Peripheral Neuropathy
- Autonomic Neuropathy



Diabetic Foot ulcers

Stages vary from different factors

DFU leads

- Infection
- Amputation
- Disability
- Death

	DIABETIC FOOT ULCER			
STAGE 0	STAGE 1	STAGE 2		
		0		
No open lesions / Healed lesions	Superficial ulcer (not penetrating into deeper	Deep ulcer (until the tendon, bone or joint)		
STAGE 3	STAGE 4	STAGE 5		
Deep ulcers with infected tissues	Partial Gangrene	Complete Gangrene		

Infection of DFU

Infection predispose to DFU , and ulcers also predispose to infections

50% ulcers associated with skin and soft tissue infection

Most common causative pathogens :

- <u>Staphylococcus spp.</u>
- <u>Streptococcus spp.</u>
- <u>Typically polymicrobial</u>

$DM \rightarrow impares immune system:$

- ↓ cytokine production
- Defects phagocytosis
- Immune cell dysfunction

If ulcers size >2cm² and/or ulcer depth >3mm \rightarrow Diabetic **osteomyelitis** (infection of the bone tissue)



Amputation of Gangrenous DFU





igure 17-21 A, Forefoot amputation status after revascularization in a 70-year-old man with diabetes mellitus, renal failure, and ecrotizing infection. Because of a limb-threatening lesion and prior contralateral limb amputation, adjunctive HBO therapy was initiated the postoperative period. B, Lesion 3 weeks later, after 21 HBO treatments and aggressive wound care. Note extensive healing. Lesion 50 days after radical debridement and split-thickness mesh graft was placed. D, Foot remained healed at 1-year follow-up.

Prevention of DFU/Diabetic footwear

- Prevention and Timely screening is a key
- (visit to Podiatrist)
- Wearing proper fit footwear (covered by insurance)
- Glycemic control (diet education)
- Infection control
- Multidisciplinary intervention (physician, podiatrist, RN, RD) for treatment is necessary



Case Study/Nutrition Assessment

HPI: Abscess of foot, cellulitis of RLE, acute osteomyelitis

Food & Nutrition Hx: 59 y.o male admitted with foot abscess, infected diabetic foot wound of right foot. Pt's PMH of DM-2, HTN. Currently, pt has a good appetite and P.O intake. Pt denies constipation, diarrhea, nausea, and vomiting.

Food intolerance: No

Food allergy: No known allergies

Feeding Ability: Independent

Appetite Evaluation: Good (>75% PO intake)

Factors Affecting PO intake: None

Pain interfering with orally intake: No

Anthropometrics:

Height: 173 cm(5'8.11")

Weight: 92.5kg (203 lb 14.8oz)

BMI: 30.9 (Overweight)

IBW: 80kg(176lb 5.9 oz)

UBW: 92.5kg (203 lbs)

Wt loss criteria: none

Patient's labs/medications

Pertinent Labs:					
Na:	and the second	K+:		Ammonia: No results found	
Sodium		Potassium		for: "NH3"	
Date/Ti Value	Ref Stat	Date/Ti Value	Ref Stat	A CONTRACTOR OF	
10/30 138	Range us	me	Range us	A Construction of the second	
/2023	136 - Fin 145 al	10/30 3.9	3.5 - Fin		
06:45	145 al mmo	/2023	5.1 al	and the second second	
AM	I/L	06:45	mmo		
Creatinine:	I/L	AM	I/L	a second s	
Creatinine		Hgb:		BUN:	
Date/Ti Value	Ref Stat	HGB		BUN	
me	Ref Stat Range us	Date/Ti Value	Ref Stat	Date/Ti Value	Ref Stat
10/30 0.50 (L)	0.70 Fin	10/30 12.3 (L)	Range us	me	Range us
/2023	- al	/2023	14.0 Fin	10/30 12	6 - Fin
06:45	1.20	06:45	- al	/2023	20 al
AM	mg/d	AM	18.0	06:45	mg/d
	L	AIM	g/dL	AM	L
Cholesterol: No		LDL: No results	found for:	Iron:	
found for: "LIPIC		"LDLD"	iouna ior.	Iron.	
iound for. En le				Date/Ti Value	Ref Stat
		A State of the second second		me	Ref Stat
		and the second second		09/20 33 (L)	45 - Fin
				/2023	165 al
		A CARLER AND A CARL		10:11	ug/d
		The second states and the		AM	l l
Glucose:		HgA1c: No resu	Its found for	: Lipase: No resu	
Glucose		"GLYC"		"LIPASE"	
Date/Ti Value	Ref Stat				
me	Range us				
10/30 240 (H)	74 - Fin	a second s			
/2023	110 al				
06:45	mg/d	and the second second			
AM	L				
				a share the second	
glucose poc capill	ary	and the second second			Contraction of the
Date/Ti Value	Ref Stat			5 Carel and a second	
me	Range us	and the second second		C. Sandara .	
10/30 283 (H)	65 - Fin			· Carton and a second	
/2023	115 al	and the second second			
12:32	mg/d	Contraction of the second second		State State State	
PM	L				
Amylase: No res		Hct:	The second second		and the second second
for: "AMYLASE"	and round	нст			
IOI. AWITLASE		Date/Ti Value	Ref Stat		
and the second second		me	Range us		
A State of the second sec		10/30 36.7 (L)	42.0 Fin		
		10,00 00. (1)			

Current Medications:

Scheduled Meds: • amLODIPine, 10 mg, Oral, Daily

- aspirin, 81 mg, Oral, Daily
- atorvastatin, 20 mg, Oral, Nightly
- enoxaparin, 40 mg, Subcutaneous, Daily
- gabapentin, 100 mg, Oral, TID
- insulin glargine, 36 Units, Subcutaneous, Q12H SCH
- insulin lispro, 0-10 Units, Subcutaneous, With meals & nightly
- insulin lispro, 17 Units, Subcutaneous, TID AC
- · losartan, 25 mg, Oral, Daily
- metFORMIN XR, 500 mg, Oral, Daily with breakfast
- vancomycin, 1,500 mg, IV Infusion, Q8H SCH

Continuous Infusions:

PRN Meds:.. acetaminophen

dextrose

glucagon

Estimated Nutritional Requirements Based on: IBW

Diet order/supplements: Diabetic Medium CCD(1800-2000 kcal)

Calories	2400	kcal/ day, based on	30	kcal/kg
Protein	96	gm/day, based on	1.2	m/kg
Fluids	2400	ml/kg, Based on	30	ml/kg

Current Nutrition Order Meets Estimated Needs: no

Nutrition Diagnosis

PES: <u>Altered nutrition status RT to DM</u> requiring modified CHO intake AEB <u>hyperglycemia</u>.

NFPE: No visual wasting observed

Does the patient have malnutrition: At risk for

Nutrition Intervention/MNT

Nutrition Education: Yes

Verbalized understanding: Provided diabetic educational materials in Russian language, explained how to count carbohydrates and how to monitor blood sugar via diet.

Expected compliance: Poor

Recommendations: Change to diabetic high CCD, supplement with Juven(90kcal, 14g of protein) 1pk/day, Vitamin B12, Vitamin C and Zinc, omega-3, supplementation for wound healing, proper hydration

Goals: Improve understanding and compliance to diet, promote healthy eating habits, improve nutrition related labs, achieve/maintain hydration, improve skin integrity.

Juven is rich with aa : Arginine & Glutamine supports DFU healing



Juven® | Therapeutic Nutrition Powder


Monitoring/Evaluation

- Maintain weight , + or -2%
- Maintain hydration
- Electrolytes WNL
- Promote wound healing
- Comply with nutrition Rx
- Improve food/nutrition related knowledge

Reassessment due date: in 5 days

Discharge plan: Discharge on recommended diet

Referral to outpatient department: Yes (needs further diabetic education)



References

McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. *Diabetes Care*. 2023;46(1):209-221. doi:10.2337/dci22-0043

Oliver TI, Mutluoglu M. Diabetic Foot Ulcer. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537328/

Wang X, Yuan CX, Xu B, Yu Z. Diabetic foot ulcers: Classification, risk factors and management. *World J Diabetes*. 2022;13(12):1049-1065. doi:10.4239/wjd.v13.i12.1049

Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. *BMC Infect Dis*. 2021;21(1):770. Published 2021 Aug 9. doi:10.1186/s12879-021-06516-7